Survival Trends of Patients with Metaplastic Breast Carcinoma with Different Hormone Receptor Statuses: a SEER-based Retrospective Cohort Study

Overview

Journal BMC Womens Health

Publisher Biomed Central

Specialty Gynecology & Obstetrics

Date 2024 Nov 27

PMID 39593066

Authors

Zhiming Miao

Futing Ba

Zechao Wen

Kai Chen

Xiang Shen

Feng Gen

Yinlong Yang

Affiliations

Soon will be listed here.

Abstract

Background: Metaplastic breast carcinoma (MpBC) is a rare histological subtype of breast cancer, and its prognosis is relatively poor. The survival trend of MpBC with different hormone receptor statuses has remained unclear over the past two decades.

Methods: MpBC patient data were collected from the Surveillance, Epidemiology, and End Results database from 2000 to 2019. Patients were divided into two groups according to their hormone receptor status (negative and positive). The survival probabilities were calculated via Kaplan‒Meier curves. Logistic regression analysis was used to obtain odds ratios for treatment and demographic characteristics. Multivariate Cox regression was used to identify prognostic factors.

Results: A total of 3,076 patients were enrolled, and a significant improvement in survival was observed over the last 10 years. For HR-negative MpBC patients, both overall survival and breast cancer-specific survival improved, whereas no survival improvement was observed for HR-positive patients. Compared with those in the time period from 2000 to 2009, the proportion of negative nodes and the likelihood of receiving chemotherapy increased for HR-negative patients from 2010 to 2019. In the HR-negative subgroup, the survival of Whites improved significantly, whereas the survival of Blacks improved in the HR-positive subgroup.

Conclusions: The survival of HR-negative MpBC patients has improved significantly in the past 20 years, which may be related to early diagnosis, increased adjuvant therapy and medical development, but no trend towards improvement has been observed in HR-positive patients. Racial disparities in different HR statuses also need to be addressed.

References

Tseng W, Martinez S . Metaplastic breast cancer: to radiate or not to radiate?. Ann Surg Oncol. 2010; 18(1):94-103. PMC: 3018259. DOI: 10.1245/s10434-010-1198-6. View

Gradishar W, Anderson B, Balassanian R, Blair S, Burstein H, Cyr A . Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018; 16(3):310-320. DOI: 10.6004/jnccn.2018.0012. View

Pezzi C, Patel-Parekh L, Cole K, Franko J, Klimberg V, Bland K . Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol. 2006; 14(1):166-73. DOI: 10.1245/s10434-006-9124-7. View

Franco P, Cante D, Sciacero P, Girelli G, La Porta M, Ricardi U . Tumor Bed Boost Integration during Whole Breast Radiotherapy: A Review of the Current Evidence. Breast Care (Basel). 2015; 10(1):44-9. PMC: 4395817. DOI: 10.1159/000369845. View

DeSantis C, Jemal A, Ward E . Disparities in breast cancer prognostic factors by race, insurance status, and education. Cancer Causes Control. 2010; 21(9):1445-50. DOI: 10.1007/s10552-010-9572-z. View

Lester T, Hunt K, Nayeemuddin K, Bassett Jr R, Gonzalez-Angulo A, Feig B . Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers. Breast Cancer Res Treat. 2011; 131(1):41-8. PMC: 3867807. DOI: 10.1007/s10549-011-1393-6. View

Wharam J, Landon B, Xu X, Zhang F, Ross-Degnan D . National Trends and Disparities in Mammography Among Commercially Insured Women, 2001-2010. J Public Health Manag Pract. 2015; 21(5):426-32. DOI: 10.1097/PHH.0000000000000101. View

Rakha E, Tan P, Varga Z, Tse G, Shaaban A, Climent F . Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. Br J Cancer. 2014; 112(2):283-9. PMC: 4453452. DOI: 10.1038/bjc.2014.592. View

Djomehri S, Gonzalez M, Veiga Leprevost F, Tekula S, Chang H, White M . Quantitative proteomic landscape of metaplastic breast carcinoma pathological subtypes and their relationship to triple-negative tumors. Nat Commun. 2020; 11(1):1723. PMC: 7138853. DOI: 10.1038/s41467-020-15283-z. View

10.

Pfeiffer R, Webb-Vargas Y, Wheeler W, Gail M . Proportion of U.S. Trends in Breast Cancer Incidence Attributable to Long-term Changes in Risk Factor Distributions. Cancer Epidemiol Biomarkers Prev. 2018; 27(10):1214-1222. PMC: 8423092. DOI: 10.1158/1055-9965.EPI-18-0098. View

11.

Murphy B, Fazzio R, Hoskin T, Glazebrook K, Keeney M, Habermann E . Management of the axilla in metaplastic breast carcinoma. Gland Surg. 2018; 7(2):200-206. PMC: 5938275. DOI: 10.21037/gs.2018.01.01. View

12.

Ong C, Campbell B, Thomas S, Greenup R, Plichta J, Rosenberger L . Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database. Ann Surg Oncol. 2018; 25(8):2249-2260. PMC: 6039971. DOI: 10.1245/s10434-018-6533-3. View

13.

John E, Phipps A, Hines L, Koo J, Ingles S, Baumgartner K . Menstrual and reproductive characteristics and breast cancer risk by hormone receptor status and ethnicity: The Breast Cancer Etiology in Minorities study. Int J Cancer. 2020; 147(7):1808-1822. PMC: 8784189. DOI: 10.1002/ijc.32923. View

14.

Akinyemiju T, Soliman A, Copeland G, Banerjee M, Schwartz K, Merajver S . Trends in breast cancer stage and mortality in Michigan (1992-2009) by race, socioeconomic status, and area healthcare resources. PLoS One. 2013; 8(4):e61879. PMC: 3639257. DOI: 10.1371/journal.pone.0061879. View

15.

Lai H, Tseng L, Chang T, Kuo Y, Hsieh C, Chen S . The prognostic significance of metaplastic carcinoma of the breast (MCB)--a case controlled comparison study with infiltrating ductal carcinoma. Breast. 2013; 22(5):968-73. DOI: 10.1016/j.breast.2013.05.010. View

16.

Zhang Y, Lv F, Yang Y, Qian X, Lang R, Fan Y . Clinicopathological Features and Prognosis of Metaplastic Breast Carcinoma: Experience of a Major Chinese Cancer Center. PLoS One. 2015; 10(6):e0131409. PMC: 4482719. DOI: 10.1371/journal.pone.0131409. View

17.

Akinyemiju T, Moore J, Ojesina A, Waterbor J, Altekruse S . Racial disparities in individual breast cancer outcomes by hormone-receptor subtype, area-level socio-economic status and healthcare resources. Breast Cancer Res Treat. 2016; 157(3):575-86. PMC: 4912843. DOI: 10.1007/s10549-016-3840-x. View

18.

Kohler B, Sherman R, Howlader N, Jemal A, Ryerson A, Henry K . Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. J Natl Cancer Inst. 2015; 107(6):djv048. PMC: 4603551. DOI: 10.1093/jnci/djv048. View

19.

Tray N, Taff J, Adams S . Therapeutic landscape of metaplastic breast cancer. Cancer Treat Rev. 2019; 79:101888. DOI: 10.1016/j.ctrv.2019.08.004. View

20.

Song Y, Liu X, Zhang G, Song H, Ren Y, He X . Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators. World J Surg Oncol. 2013; 11:129. PMC: 3679991. DOI: 10.1186/1477-7819-11-129. View